Treatment with anti-sclerostin antibody prevents myeloma-induced bone loss in the 5TGM1 murine model of myeloma. (A) Schematic depicting study design for 5TGM1 studies. (B) 3D microCT reconstructions of distal femora representing each treatment group in experiment (Expt) 2. (C) Dot plot of the ratio of trabecular bone volume to total volume (BV/TV) from distal femora of experiment 1 (n = 5-6) and experiment 2 (n = 8) (data are mean ± 1 SEM). (D) 3D microCT reconstructions of L4 vertebrae representing L4 from each treatment group in experiment 2. (E) Dot plot of trabecular BV/TV from lumbar vertebra 2 (L2) from experiment 1 (n = 6) and lumbar vertebra 4 (L4) from experiment 2 (n = 8) (data are mean ± 1 SEM; *P < .05; **P < .01; ***P < .001; ****P < .0001). BM, bone marrow; CB, cortical bone; GP, growth plate; i.v., intravenous; s.c., subcutaneous; Scl, sclerostin; TB, trabecular bone.